Seqera appoints Melinda Pautsch as Chief Revenue Officer
Seqera announced today the appointment of Melinda Pautsch as its Chief Revenue Officer (CRO). The appointment marks a significant step in the company’s growth journey, as it focuses on strengthening its market position as the open science platform of choice and delivering value for customers across the Nextflow ecosystem.
In her new role, Pautsch will be responsible for overseeing all sales and sales development efforts within Seqera, while establishing the next phase of the go-to market strategy. She will also play a critical role in shaping Seqera’s growth, working with CEO and co-founder Evan Floden, to meet and exceed the company’s ambitious goals.
Prior to joining Seqera, Pautsch held various leadership positions in the life sciences research and development (R&D) sector. Her most recent role was at Medidata (now part of Dassault Systemes), where she spent 12 years building and leading the MedTech market segment. During her time at Medidata, she established a global team focused on advancing the use of technology platforms to impact R&D, clinical research, and manufacturing processes across the MedTech development lifecycle.
Pautsch spent the first decade of her career in commercial leadership positions at several startups including Xceleron and Cyprotex, helping advance drug discovery and preclinical development. She studied Biochemistry at Villanova University, pursued graduate chemistry work at the University of Pennsylvania, and completed advanced business courses at INSEAD and Columbia University.
Commenting on her appointment, CEO and co-founder Evan Floden said:
“We’re delighted to welcome Melinda as Chief Revenue Officer. Her joining represents a significant milestone in our growth as a company since our inception in 2018. Her deep understanding of the biopharma landscape, coupled with her impressive track record in driving revenue growth within the sector makes her an invaluable addition to our leadership team. We look forward to having her on board and working with customers to ensure their science leads to success.”
Melinda Pautsch, Chief Revenue Officer said:
“I’m thrilled to be joining the Seqera team and to contribute to its ongoing success. Seqera’s market-leading workflow and data management solutions were already the tool of choice for leading scientists, and that is a testament to the team’s dedication and commitment to innovation. Over the past six years, Seqera has made significant strides in the industry, and I’m excited to be a part of the journey ahead.”
About Seqera
Seqera makes complex data analysis accessible at any scale by providing the tools to drive innovation in genomics, global health, and beyond. The company provides software for scientists solving today’s most complex and important challenges from pioneering innovative therapeutics to unveiling the secrets of our universe. The journey began a decade ago with Nextflow — open software that helps over 100,000 global scientists analyze and process data, with more power and flexibility than ever before. Today, Seqera consolidates fragmented data and diverse computing resources into a unified platform. Their modern biotech stack is trusted by 150 leading life sciences organizations including AstraZeneca, Roche, and Johnson & Johnson. Empowered with modern software engineering, organizations conduct science faster, on larger datasets, and with more confidence. Seqera accelerates discoveries in an open world.
Media Contact
Emily Owen
+447807486108